Slide background
Department of Pharmacology

Department of Pharmacology

Department of Pharmacology was founded in Mersin University Faculty of Pharmacy Department of Professional Pharmaceutical Sciences at 09/10/2001. Currently, 3 lecturers and 3 research assistants continue to the education and the research at associate degree, graduate, and postgraduate grades. Until now, in our department 10 students of the master programme and 3 students of the doctorate programme has graduated with “Master of Science” and “Doctor of Philosophy” titles. Currently, 5 master and 3 Ph.D. students continue to their education.

The academic staff of our department have continued to do their original research with educational activities and publish the results of these studies in national/international peer-reviewed journals/books since 2001-2002 academic year. In our department, possible therapeutic approaches to the treatment of diseases associated with hypotension, inflammation, and organ damage are investigated in septic and nonseptic shock, pain, and ischemia-reperfusion models These research activities are supported by several institutions including Mersin University, TUBITAK, and Novartis.

The academic staff of our departmant serve as a chairman or member in various committees in our university including Clinical Research Ethics Committee, Experimental Animals Local Ethics Committee, and Environmental Ethics Committee. Our academic staff also participate in educational activities regarding rational drug use as trainers organized by various institutions. Our academic staff also serve as editor or reviewer in various national and international journals as well as panelist, reviewer, or adviser in the research projects supported by TUBITAK, European Commission, and diverse universities.

 


Publications in International Scientific Journals(last two years)

2021
14. şenol, .; Temiz reşitoğlu, M.; Güden, D.; Sarı, A.; şahan fırat, S.; Tunçtan, B. Suppression of TLR4/MyD88/TAK1/NF-κB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model. NEUROCHEMICAL RESEARCH, 2021, ---.
10.1007/s11064-020-03197-7
13. Güden, D.; Temiz reşitoğlu, M.; şenol , .; Kibar, D.; Yılmaz, .; Tunçtan, B.; Malik, K.; şahan fırat, S. mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by lipopolysaccharide challenge in rats. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, ---, ---.
12. Cagli, A.; Senol, S.; Temiz‐resitoglu, M.; Guden, D.; Sari, A.; Sahan‐firat, S.; Tunctan, B. Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl‐3‐(1‐propionylpiperidin‐4‐yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome‐related pro‐inflammatory and anti‐inflammatory signaling pathways .... WILEY, 2021, 0-0.
http://dx.doi.org/10.1002/ddr.21786
11. Senol, S.; Temiz-resitoglu, M.; Guden, D.; Sari, A.; Sahan-firat, S.; Tunctan, B. Suppression of TLR4/MyD88/TAK1/NF-κB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model. SPRINGER SCIENCE AND BUSINESS MEDIA LLC, 2021, 46, 624-637.
http://dx.doi.org/10.1007/s11064-020-03197-7
2020
10. Tiftik, R.; Temiz reşitoğlu, M.; Güden, D.; Bayrak, G.; Yılmaz, .; ün, .; şahan fırat, S. Involvement of Rho-kinase/IκB-α/NF-κB activation in IL-1β induced inflammatory response and oxidative stress in human chondrocytes. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2020, ---.
9. Biliktu, M.; Senol, S.; Temiz-resitoglu, M.; Guden, D.; Horat, M.; Sahan-firat, S.; Sevim, S.; Tunctan, B. Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner. SPRINGER SCIENCE AND BUSINESS MEDIA LLC, 2020, 0-0.
http://dx.doi.org/10.1007/s10787-020-00691-w
8. Tunctan, B. CYP-derived eicosanoids in inflammatory diseases. ELSEVIER BV, 2020, 148, 106424-106424.
http://dx.doi.org/10.1016/j.prostaglandins.2020.106424
7. Biliktu, M.; Senol, S.; Temiz-resitoglu, M.; Guden, D.; Horat, M.; Sahan-firat, S.; Sevim, S.; Tunctan, B. Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner. INFLAMMOPHARMACOLOGY, 2020, 28, 1509-1524.
http://dx.doi.org/10.1007/s10787-020-00691-w
6. Biliktu, M.; şenol, .; Temiz reşitoğlu, M.; Güden, D.; Horat, F.; şahan fırat, S.; Sevim, S.; Tunçtan, B. . INFLAMMOPHARMACOLOGY, 2020, , -.
2019
5. Tunctan, B.; Senol, S.; Temiz-resitoglu, M.; Guden, D.; Sahan-firat, S.; Falck, J.; Malik, K. Eicosanoids derived from cytochrome P450 pathway of arachidonic acid and inflammatory shock. ELSEVIER BV, 2019, 145, 106377-106377.
http://dx.doi.org/10.1016/j.prostaglandins.2019.106377
4. Tunçtan, B.; şenol, .; Temiz reşitoğlu, M.; Güden, D.; şahan fırat, S.; Falck, J.; Malik, K. Eicosanoids derived from cytochrome P450 pathway of arachidonic acid and inflammatory shock. PROSTAGLANDINS OTHER LIPID MEDIATORS, 2019, 145, 106377-.
10.1016/j.prostaglandins.2019.106377
3. Kocak, Z.; Temiz-resitoglu, M.; Guden, D.; Vezir, O.; Sucu, N.; Balcı, S.; Tamer-gumus, L.; Tunctan, B.; Malik, K. Modulation of oxidative–nitrosative stress and inflammatory response by rapamycin in target and distant organs in rats exposed to hindlimb ischemia–reperfusion: the role of mammalian target of rapamycin. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2019, 97, 1193-1203.
http://dx.doi.org/10.1139/cjpp-2019-0394
2. şahan fırat, S.; Temiz reşitoğlu, M.; Güden, D.; şenol, .; Sarı, A.; çil, M.; ünsal, D.; Korkmaz, B.; Tunçtan, B. NF-κB activation mediates LPS- or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2019, 46, 173-182.
10.1111/1440-1681.13045
1. Tunçtan, B.; şenol, .; Temiz reşitoğlu, M.; Güden, D.; şahan fırat, S.; Falck, J.; Ku, M. . PROSTAGLANDINS OTHER LIPID MEDIATORS, 2019, , -.